 |
English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12145/12927 (94%)
Visitors : 908367
Online Users : 1021
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/7962
|
| Title: | Silica nanoparticle platform |
| Authors: | Souris, JS;Chen, NT;Cheng, SH;Chen, CT;Lo, LW |
| Contributors: | Division of Medical Engineering Research |
| Abstract: | Cancer nanotheranostics employ multifunctional, nanometer-scale, organic and inorganic materials to extract diagnostic insight and deliver pathology-targeted therapy. The fundamental advantage of combining such seemingly disparate objectives is the ability to use patient-specific test results to tailor treatment programs that result in improved clinical outcomes, reduced costs, and minimal side effects. Such platforms also enable in vivo monitoring of both the nanomaterial’s biodistribution and fate and its therapeutic progress and efficacy throughout the course of treatment. In contrast to most other nanomaterials, whose physicochemical properties differ markedly from those of their corresponding bulk forms, silica nanomaterials generally do not acquire any new or unusual characteristics from the diminution of their size, other than a corresponding increase in surface area. Rather, their utility stems from the ease with which their surfaces can be functionalized and their ability to form both solid and porous structures, the latter of which greatly enhances the surface area and different topologies available for synergistic applications such as protected codelivery of therapeutics and imaging contrast agents. Silica nanoparticles are inexpensive and simple to synthesize, chemically inert, biocompatible/excretable, and easily dispersed in water. Silica nanoparticles are also effectively “transparent” at UV, visible, and near-infrared (NIR) wavelengths and unaffected by electric or magnetic fields—attributes that facilitate their external visualization and manipulation. This chapter presents some of the more noteworthy recent advances in the development and evaluation of silica nanoparticle platforms as theranostic agents, and discusses hurdles that remain to be addressed prior to their clinical translation. |
| Date: | 2014-03 |
| Relation: | Cancer Theranostics. 2014 Mar;Chapt 20:363-391. |
| Link to: | http://dx.doi.org/10.1016/B978-0-12-407722-5.00020-7 |
| Cited Times(Scopus): | http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84902402565 |
| Appears in Collections: | [羅履維] 圖書
|
Files in This Item:
There are no files associated with this item.
|
All items in NHRI are protected by copyright, with all rights reserved.
|
